Johnathan Wiese
Primary Care · Saint Louis, MONPI 1487130746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $555 and has fallen 87.7% since, to $68 in 2025.
Across 105 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$422
- UCB, Inc.$233
- CSL Behring$208
- Johnson & Johnson$163
- Boston Scientific$163
- AstraZeneca$140
- plus $658 from 12 others
What the payments were for
- Food & beverage$1,93297%
- Education$553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 29 | $422 |
| UCB, Inc. | 10 | $233 |
| CSL Behring | 10 | $208 |
| Johnson & Johnson | 8 | $163 |
| Boston Scientific | 7 | $163 |
| AstraZeneca(2 entities) | 9 | $140 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Neurelis, Inc. | 1 | $92 |
| Pfizer | 6 | $87 |
| SK Life Science, Inc. | 3 | $69 |
| Avanir Pharmaceuticals, Inc. | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Genentech USA, Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
| Microtransponder, Inc. | 1 | $14 |
How this compares
$1,987 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $92,453 |
| Repatha SureclickEvolocumab | 75 | $88,409 |
| XareltoRivaroxaban | 56 | $77,418 |
| XcopriCenobamate | 13 | $23,682 |
| Praluent PenAlirocumab | 19 | $18,647 |
| Ezetimibe | 147 | $3,211 |
| Atorvastatin Calcium | 229 | $2,472 |
| Rosuvastatin Calcium | 161 | $2,315 |
| ClopidogrelClopidogrel Bisulfate | 121 | $1,538 |
| Levetiracetam | 50 | $1,516 |
| Oxcarbazepine | 11 | $745 |
| Gabapentin | 25 | $726 |
| Levetiracetam ErLevetiracetam | 13 | $552 |
| Amlodipine Besylate | 37 | $207 |
| Losartan Potassium | 16 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $92,45371 claims |
| Johnson & JohnsonXarelto | $163 | $77,41856 claims |
| SK Life Science, Inc.Xcopri | $69 | $23,68213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 primary care providers in Missouri.
Other primary care in Saint Louis
- Joy MurphySaint Louis$7K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Heather BealSaint Louis$4K
- Ashley TitchenalSaint Louis$3K
- Brittany ShoultsSaint Louis$3K
- Stella HeineSaint Louis$2K
- Taylor RouserSaint Louis$2K
- Faye MonahanSaint Louis$1K
- Alita BillopsSaint Louis$840
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.